search
Back to results

Digital Metabolic Rehab COPD

Primary Purpose

Metabolic Syndrome, Chronic Obstructive Pulmonary Disease

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Digital Metabolic Rehab
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Metabolic Syndrome focused on measuring Web-based platform, Nutrition, Physical activity, Mindfulness, Primary care, Metabolic syndrome, COPD

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult patients (18+) COPD stage 1 or 2 Identified by their family doctor as having at least two out of five MetS factors Adjusted body mass index (BMI) between 26 to 40 Able to provide written informed consent in English Exclusion Criteria: Inability to speak, read or understand English Having a medical or physical condition that makes moderate-intensity physical difficult or unsafe Diagnosis of Type 1 diabetes mellitus or type 2 diabetes mellitus with proliferative diabetic retinopathy, nephropathy (serum creatine > 160 µmol/L), clinically significant neuropathy (defined as absent ankle jerks), severe hyperglycemia (fasting blood glucose > 11 mmol/L), or claudication symptoms Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal, liver), COPD stages 3 or 4, heart failure stage D, stroke, and ongoing substance abuse, undergoing active treatment for cancer Clinically significant renal failure (.i.e., creatinine > 200 µmol/L) Diagnosis of psychiatric disorders that would limit the adequate ability to comply with the study protocol Unable or unwilling to use technology to meet with the healthcare team and My Viva Plan to manage self-care

Sites / Locations

  • University of AlbertaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single-arm pilot trial

Arm Description

The Digital Metabolic Rehab is a single-arm pilot trial that assesses Canadian Digital Technology's feasibility in preventing and managing MetS in patients living with COPD for a 12-month program.

Outcomes

Primary Outcome Measures

Metabolic Syndrome
Proportion of patients achieving reversal of Metabolic Syndrome (no longer meeting 3 of 5 diagnostic criteria)
Waist circumference
Proportion of patients achieving reduction in waist circumference.
Blood pressure
Proportion of patients achieving reduction in systolic and diastolic blood pressure. Systolic and diastolic blood pressure will be measured using a standard semi-automatic sphygmomanometer.

Secondary Outcome Measures

Changes in body weight
Changes in body weight will be measured using calibrated digital scale (Health o meter® Professional Remote Display, Sunbeam Products Inc., Fla., USA)
Changes in and body mass index (BMI)
The intervention's ability to promote changes in BMI (weight and height will be combined to report BMI in kg/m^2)
Changes in fat mass
Changes in fat mass (kg) by bioelectrical impedance analysis
Changes in phase angle
Changes in phase angle is assessed by bioelectrical impedance analysis
Changes in fat-free mass
Changes in fat-free mass (kg) by bioelectrical impedance analysis
Changes in muscle cross sectional area
Changes in muscle cross sectional area (cm2) by ultrasound
Changes in muscle echogenicity
Changes in muscle echogenicity by ultrasound
Changes in muscle strength
Changes in muscle strength assessed by handgrip strength
Changes in physical performance
Changes in physical performance assessed by 6-minute walk test
Changes in fitness assessment
Changes in fitness test are assessed using the maximum number of partial curl-ups (up to 25) and push-ups performed in one minute.
Changes in flexibility test
Changes in trunk flexion range of motion will be evaluated using inertial measuring units during bending in standing position.
Changes in resting energy expenditure
Changes in resting energy expenditure assessed by indirect calorimetry

Full Information

First Posted
March 3, 2023
Last Updated
April 7, 2023
Sponsor
University of Alberta
Collaborators
Revive Wellness Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05806294
Brief Title
Digital Metabolic Rehab COPD
Official Title
Utilizing Canadian Digital Technology to Prevent and Manage Diabetes, Obesity, and Heart Disease in Patients Living With Congestive Obstructive Pulmonary Disease - A Single-arm Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 17, 2022 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alberta
Collaborators
Revive Wellness Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
People with Chronic Obstructive Pulmonary Disease (COPD) are at greater risk for Metabolic syndrome (MetS). Although the management of MetS will not cure COPD, it can beneficially impact health outcomes and quality of life through lifestyle modifications. The study aims to determine if using the Digital Metabolic Rehab program, which is based on preventive self-care and includes three key pillars of health: nutrition, fitness, and mindfulness, will be feasible to reduce or reverse MetS for individuals living with COPD.
Detailed Description
It is estimated that 50% of patients with Chronic Obstructive Pulmonary Disease (COPD) are at risk for having Metabolic Syndrome (MetS). While COPD is incurable, MetS can be reduced by diet and exercise. Yet, the evidence shows that lifestyle interventions with the self-management of health at home are low. Thus, the Canadian Health Advanced by Nutrition and Graded Exercise (CHANGE) protocol and My Viva Plan® (MVP) were created. CHANGE protocol is a personalized approach to nutrition and exercise modification supported by an interprofessional team in primary care settings. MVP is a digital Canadian self-care treatment program encompassing nutrition, fitness, and mindfulness. The investigators propose a 12-month Digital Metabolic Rehab program using CHANGE protocol + MVP to guide diet and self-awareness in 50 individuals diagnosed with COPD and MetS. Assessments and measurements will be completed at baseline, 3 and 12 months. The study aims to determine the impact of the CHANGE protocol + MVP on reducing or reversing MetS for individuals living with COPD. This study will inform whether the Digital Metabolic Rehab program directly impacts health and wellness among patients with COPD and could become an essential tool for virtual, preventative self-care delivery in primary care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Chronic Obstructive Pulmonary Disease
Keywords
Web-based platform, Nutrition, Physical activity, Mindfulness, Primary care, Metabolic syndrome, COPD

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single-arm pilot trial
Arm Type
Experimental
Arm Description
The Digital Metabolic Rehab is a single-arm pilot trial that assesses Canadian Digital Technology's feasibility in preventing and managing MetS in patients living with COPD for a 12-month program.
Intervention Type
Behavioral
Intervention Name(s)
Digital Metabolic Rehab
Intervention Description
The Digital Metabolic Rehab combines two programs: The Canadian Health Advanced by Nutrition and Graded Exercise protocol (CHANGE) and My Viva Plan (MVP). All participants receive free access to MVP and attend group video conferencing sessions with health professionals. After the 60-minute initial assessments with the dietitian and the kinesiologist, each participant has an individualized diet and exercise plan based on the intervention protocol built in MVP. Participants are split into groups of 10 based on physical ability and stage of COPD. Intervention starts in phase 1. During phase 1 (first three months), participants have weekly videoconference group sections with the kinesiologist and the dietitian and monthly with the psychologist and the respiratory therapist. Phase 2 starts from month 4 to month 12, and the video conference group sessions with health professionals are transitioned to monthly sessions.
Primary Outcome Measure Information:
Title
Metabolic Syndrome
Description
Proportion of patients achieving reversal of Metabolic Syndrome (no longer meeting 3 of 5 diagnostic criteria)
Time Frame
Change From baseline to month 3 and month 12
Title
Waist circumference
Description
Proportion of patients achieving reduction in waist circumference.
Time Frame
Change From baseline to month 3 and month 12
Title
Blood pressure
Description
Proportion of patients achieving reduction in systolic and diastolic blood pressure. Systolic and diastolic blood pressure will be measured using a standard semi-automatic sphygmomanometer.
Time Frame
Change From baseline to month 3 and month 12
Secondary Outcome Measure Information:
Title
Changes in body weight
Description
Changes in body weight will be measured using calibrated digital scale (Health o meter® Professional Remote Display, Sunbeam Products Inc., Fla., USA)
Time Frame
From baseline to month 3 and month 12
Title
Changes in and body mass index (BMI)
Description
The intervention's ability to promote changes in BMI (weight and height will be combined to report BMI in kg/m^2)
Time Frame
From baseline to month 3 and month 12
Title
Changes in fat mass
Description
Changes in fat mass (kg) by bioelectrical impedance analysis
Time Frame
From baseline to month 3 and month 12
Title
Changes in phase angle
Description
Changes in phase angle is assessed by bioelectrical impedance analysis
Time Frame
From baseline to month 3 and month 12
Title
Changes in fat-free mass
Description
Changes in fat-free mass (kg) by bioelectrical impedance analysis
Time Frame
From baseline to month 3 and month 12
Title
Changes in muscle cross sectional area
Description
Changes in muscle cross sectional area (cm2) by ultrasound
Time Frame
From baseline to month 3 and month 12
Title
Changes in muscle echogenicity
Description
Changes in muscle echogenicity by ultrasound
Time Frame
From baseline to month 3 and month 12
Title
Changes in muscle strength
Description
Changes in muscle strength assessed by handgrip strength
Time Frame
From baseline to month 3 and month 12
Title
Changes in physical performance
Description
Changes in physical performance assessed by 6-minute walk test
Time Frame
From baseline to month 3 and month 12
Title
Changes in fitness assessment
Description
Changes in fitness test are assessed using the maximum number of partial curl-ups (up to 25) and push-ups performed in one minute.
Time Frame
From baseline to month 3 and month 12
Title
Changes in flexibility test
Description
Changes in trunk flexion range of motion will be evaluated using inertial measuring units during bending in standing position.
Time Frame
From baseline to month 3 and month 12
Title
Changes in resting energy expenditure
Description
Changes in resting energy expenditure assessed by indirect calorimetry
Time Frame
From baseline to month 3 and month 12
Other Pre-specified Outcome Measures:
Title
Changes in quality of life parameters
Description
Changes in scores of quality of life are assessed by the Chronic Respiratory Questionnaire (CRQ). The Items are scaled in Numerical, 7-point modified Likert Scale. Higher scores indicate a better health-related quality of life
Time Frame
From baseline to month 3 and month 12
Title
Changes in SF-12 score
Description
Changes in physical and mental well-being are assessed in 8 domains (physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health) by the Short Form 12 (SF-12).
Time Frame
From baseline to month 3 and month 12
Title
Changes in cardiovascular disease risk
Description
Changes in cardiovascular disease risk by Prospective Cardiovascular Munster scores (PROCAM). PROCAM predicts cardiovascular risk in 10 years (<1% to > 40%). The higher the scores, the greater the cardiovascular risk
Time Frame
From baseline to month 3 and month 12
Title
Well being changes
Description
Changes in well-being are assessed by the World Health Organization Well-Being Index (WHO-5). The raw scores are transformed to a score from 0 to 100, with lower scores indicating worse well-being
Time Frame
From baseline to month 3 and month 12
Title
Mental health
Description
Mental health and depression are assessed by the Patient Health Questionnaire - 9 (PHQ-9). PHQ-9 score will be obtained by adding the score for each question (total points). Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively
Time Frame
From baseline to month 3 and month 12
Title
Changes in psychosocial determinants of behavioral
Description
Physical Activity Readiness Questionnaire (PAR-Q+) will be used to assess the readiness of participants to engage in physical activity and determines any safety and possible risks that could be impacted by physical activity
Time Frame
From baseline to month 3 and month 12
Title
Changes in hospital admissions rates for exacerbation of COPD
Description
Exacerbation of COPD events is measured by outpatient visits, emergency room visits, and hospitalizations
Time Frame
From baseline to month 12
Title
Changes in hospital admissions rates for myocardial infarction events
Description
Myocardial infarction events are measured by outpatient visits, emergency room visits, and hospitalizations
Time Frame
From baseline to month 3 and month 12
Title
Changes in hospital admissions rates for ischemic stroke events
Description
Ischemic stroke events are measured by outpatient visits, emergency room visits, and hospitalizations
Time Frame
From baseline to month 3 and month 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult patients (18+) COPD stage 1 or 2 Identified by their family doctor as having at least two out of five MetS factors Adjusted body mass index (BMI) between 26 to 40 Able to provide written informed consent in English Exclusion Criteria: Inability to speak, read or understand English Having a medical or physical condition that makes moderate-intensity physical difficult or unsafe Diagnosis of Type 1 diabetes mellitus or type 2 diabetes mellitus with proliferative diabetic retinopathy, nephropathy (serum creatine > 160 µmol/L), clinically significant neuropathy (defined as absent ankle jerks), severe hyperglycemia (fasting blood glucose > 11 mmol/L), or claudication symptoms Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal, liver), COPD stages 3 or 4, heart failure stage D, stroke, and ongoing substance abuse, undergoing active treatment for cancer Clinically significant renal failure (.i.e., creatinine > 200 µmol/L) Diagnosis of psychiatric disorders that would limit the adequate ability to comply with the study protocol Unable or unwilling to use technology to meet with the healthcare team and My Viva Plan to manage self-care
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bruna Ramos da Silva, PhD
Phone
780-492-7820
Email
ramosdas@ualberta.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Doug Klein, MD
Organizational Affiliation
University of Alberta
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Liam Collins, MS
Organizational Affiliation
University of Alberta
Official's Role
Study Director
Facility Information:
Facility Name
University of Alberta
City
Edmonton
State/Province
Alberta
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruna Ramos da Silva, PhD
Phone
780-492-7820
Email
ramosdas@ualberta.ca
First Name & Middle Initial & Last Name & Degree
Doug Klein, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.changealberta.net/
Description
CHANGE Alberta website
URL
https://discover.myvivaplan.com/
Description
My Viva Plan website

Learn more about this trial

Digital Metabolic Rehab COPD

We'll reach out to this number within 24 hrs